Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

P. R. Bargo; S. L. Jacques

doi:10.1117/12.434744

Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

P. R. Bargo, S. L. Jacques

Research output: Contribution to journal › Conference article › peer-review

1 Scopus citations

Abstract

The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

Original language	English (US)
Pages (from-to)	50-56
Number of pages	7
Journal	Proceedings of SPIE - The International Society for Optical Engineering
Volume	4257
DOIs	https://doi.org/10.1117/12.434744
State	Published - 2001
Externally published	Yes
Event	Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical - San Jose, CA, United States Duration: Jan 21 2001 → Jan 24 2001

Keywords

Dosimetry
Fluorescence
Optics
PDT
Photodynamictherapy
Reflectance

ASJC Scopus subject areas

Electronic, Optical and Magnetic Materials
Condensed Matter Physics
Computer Science Applications
Applied Mathematics
Electrical and Electronic Engineering

Access to Document

10.1117/12.434744

Cite this

@article{2a001ed05dee49b9839f980b4bc9d233,

title = "Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT",

abstract = "The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.",

keywords = "Dosimetry, Fluorescence, Optics, PDT, Photodynamictherapy, Reflectance",

author = "Bargo, {P. R.} and Jacques, {S. L.}",

year = "2001",

doi = "10.1117/12.434744",

language = "English (US)",

volume = "4257",

pages = "50--56",

journal = "Proceedings of SPIE - The International Society for Optical Engineering",

issn = "0277-786X",

publisher = "SPIE",

note = "Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical ; Conference date: 21-01-2001 Through 24-01-2001",

}

TY - JOUR

T1 - Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

AU - Bargo, P. R.

AU - Jacques, S. L.

PY - 2001

Y1 - 2001

N2 - The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

AB - The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

KW - Dosimetry

KW - Fluorescence

KW - Optics

KW - PDT

KW - Photodynamictherapy

KW - Reflectance

UR - http://www.scopus.com/inward/record.url?scp=0034877323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034877323&partnerID=8YFLogxK

U2 - 10.1117/12.434744

DO - 10.1117/12.434744

M3 - Conference article

AN - SCOPUS:0034877323

SN - 0277-786X

VL - 4257

SP - 50

EP - 56

JO - Proceedings of SPIE - The International Society for Optical Engineering

JF - Proceedings of SPIE - The International Society for Optical Engineering

T2 - Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical

Y2 - 21 January 2001 through 24 January 2001

ER -

Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this